Диссертация (1139881), страница 14
Текст из файла (страница 14)
149, pp. 7680.66.Geerts WH, Heit JA, Clagett GP, et a. Prevention of venousthromboembolism // Chest, 2001, No. 119, (Suppl 1), pp. 132S–175S.67.Gibbons R, Greenland P, Lackland DT, et al; American College ofCardiology/American Heart Association Task Force on Practice Guidelines. 2013ACC/AHA guideline on the assessment of cardiovascular risk: a report of the112American College of Cardiology/American Heart Association Task Force onPractice Guidelines // Circulation, 2014, No.
129 (suppl 2), pp. S49–S73.68.Gili Kenet, Lisa K. Lütkhoff, Manuela Albisetti, Timothy Bernard.Impact of Thrombophilia on Risk of Arterial Ischemic Stroke or CerebralSinovenous Thrombosis in Neonates and Children. A Systematic Review andMeta-Analysis of Observational Studies // Circulation, 2010, Vol. 121, No. 16,pp. 1838-47.69.Global Burden of Disease Study 2013 Collaborators. Global,regional, and national incidence, prevalence, and years lived with disability for301 acute and chronic diseases and injuries in 188 countries, 1990–2013: asystematic analysis for the Global Burden of Disease Study 2013 // Lancet, 2015,No. 386, pp.
743–800.70.Global Burden of Disease Study 2013 Mortality and Causes of DeathCollaborators. Global, regional, and national age-sex specific all-cause and causespecific mortality for 240 causes of death, 1990–2013: a systematic analysis forthe Global Burden of Disease Study // Lancet, 2015, Vol.
385, pp. 117-171.71.Global Status Report on Noncommunicable Diseases 2014. Geneva,Switzerland:WorldHealthOrganization;2014.http://apps.who.int/iris/bitstream/10665/148114/1/9789241564854_eng.pdf.(Accessed September 2, 2016).72.Haemostasis and Thrombosis Task Force, British Committee forStandards in Haematology. Investigation and management of heritablethrombophilia // Br J Haematol, 2001, Vol. 114, No.
3, pp. 512-28.73.Heit JA, Ashrani A, Crusan DJ, McBane RD, Petterson TM, BaileyKR. Reasons for the persistent incidence of venous thromboembolism // ThrombHaemost. 2017, Vol. 2, No. 117, pp. 390-400.74.Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep veinthrombosis and pulmonary embolism: a population-based case-control study //Arch Intern Med, 2000, No. 160, pp. 809–815.11375.Heit JA. Poster 68 presented at: American Society of Hematology.Atlanta, GA: 47th Annual Meeting, 2005.76.Hendrix SL, Wassertheil-Smoller S, Johnson KC, et al; WHIInvestigators. Effects of conjugated equine estrogen on stroke in the Women’sHealth Initiative // Circulation, 2006, No.
113, pp. 2425–2434.77.Hindorff LA, Schwartz SM, Siscovick DS, Psaty BM, LongstrethWT Jr, Reiner AP. The association of PAI-1 promoter 4G/5G insertion/deletionpolymorphism with myocardial infarction and stroke in young women // JCardiovasc Risk, 2002, Vol.
9, No. 2, pp. 131-7.78.Hippisley-Cox J, Coupland C. Development and validation of riskprediction algorithm (QThrombosis) to estimate future risk of venousthromboembolism: prospective cohort study // BMJ, 2011, No. 343, P. d4656.79.Holmqvist ME, Neovius M, Eriksson J et al. Risk of venousthromboembolism in patients with rheumatoid arthritis and association withdisease duration and hospitalization // JAMA, 2012, No. 308, pp. 1350–1356.80.Horvei LD, Brækkan SK, Mathiesen EB, Njølstad I, Wilsgaard T,Hansen JB.
Obesity measures and risk of venous thromboembolism andmyocardial infarction // Eur J Epidemiol, 2014, Vol. 29, No. 11, pp. 821-30.81.Hu X, Zan X, Xie Z, Li Y, Lin S, Li H, You C. Association BetweenPlasminogenActivatorInhibitor-1GeneticPolymorphismsandStrokeSusceptibility // Mol Neurobiol, 2017, Vol. 54, No.
1, pp. 328-341.82.Institute for Health Metrics and Evaluation (IHME). Global Burdenof Disease Data Visualizations. GBD Compare. Global, deaths, both sexes, allages, 2015. Seattle, WA, University of Washington; 2015: GBD Compare DataVisualization. http://vizhub.healthdata.org/gbd-compare, (Accessed, 2016).83.ISTH Steering Committee for World Thrombosis. Thrombosis: amajor contributor to the global disease burden // J Thromb Haemost, 2014, No.12, pp. 1580-90.84.Jamison DT, Summers LH, Alleyne G, Arrow KJ, Berkley S,Binagwaho A, Bustreo F, Evans D, Feachem RG, Frenk J, Ghosh G, Goldie SJ,114Guo Y, Gupta S, Horton R, Kruk ME, Mahmoud A, Mohohlo LK, Ncube M,Pablos-Mendez A, et al. Global health 2035: a world converging within ageneration.
// Lancet, 2013, No. 382, pp. 1898–955.85.Jha AK, Larizgoitia I, Audera-Lopez C, Prasopa-Plaisier N, WatersH, Bates DW. The global burden of unsafe medical care: analytic modeling ofobservational studies // BMJ Qual Saf 2013, 2013, No. 22, pp. 809-15.86.Kahn S, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, CookDJ, Balekian AA, Klein RC, Le H, Schulman S, Murad MH. in nonsurgicalpatients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed:American College of Chest Physicians Evidence-based Clinical PracticeGuidelines // Chest, 2012, Vol. 141, No. 2, pp. e195S–226S.87.Kang S, Zhao X, Liu L, Wu W, Zhang D.
Association of the C677Tpolymorphism in the MTHFR gene with hemorrhagic stroke: a meta-analysis //Genet Test Mol Biomarkers, 2013, No. 17, pp. 412-7.88.Karasu A, Cushman M, Rosendaal FR, Hylckama Vlieg A. Lungdiseases in the elderly increase the risk of pulmonary embolism more than ofdeep vein thrombosis // Abstracts of the 10th International Congress of theEuropean Union Geriatric Medicine Society - Geriatric Medicine CrossingBorders, 2014, Vol. 5, No. 1, P. S65.89.Kaye SM, Pietiläinen KH, Kotronen A, Joutsi-Korhonen L, Kaprio J,Yki-Järvinen H, Silveira A, Hamsten A, Lassila R, Rissanen A. Obesity-relatedderangements of coagulation and fibrinolysis: a study of obesity-discordantmonozygotic twin pairs // Obesity (Silver Spring), 2012, Vol.
20, No. 1, 88-94.90.Kearon C, Ageno W, Cannegieter SC, Cosmi B, Geersing GJ, KyrlePA; Subcommittees on Control of Anticoagulation, and Predictive and DiagnosticVariables in Thrombotic Disease. Categorization of patients as having provokedor unprovoked venous thromboembolism: guidance from the SSC of ISTH // JThromb Haemost, 2016, Vol. 14, No.
7, pp. 1480-3.11591.Kearon C, Akl EA, Ornelas J, Blaivas A,. Antithrombotic Therapyfor VTE Disease: CHEST Guideline and Expert Panel Report // Chest, 2016, Vol.149, No. 2, pp. 315-52.92.Khoury JC, Kleindorfer D, Alwell K, et al. Diabetes mellitus: a riskfactor for ischemic stroke in a large biracial population // Stroke, 2013, No. 44,pp. 1500–1504.93.Kim V, Goel N, Gangar J et al. Risk Factors for VenousThromboembolism in Chronic Obstructive Pulmonary Disease // Chronic ObstrPulm Dis, 2014, Vol.
1, No. 2, pp. 239–249.94.Klein S, Burke LE, Bray GA, et al; American Heart AssociationCouncil on Nutrition, Physical Activity, and Metabolism. Clinical implications ofobesity with specific focus on cardiovascular disease: a statement forprofessionals from the American Heart Association Council on Nutrition,Physical Activity, and Metabolism // Circulation, 2004, No.
110, pp. 2952–2967.95.Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG,MTHFR Studies Collaboration Group. MTHFR 677C–>T polymorphism and riskof coronary heart disease: a meta-analysis // JAMA, 2002, No. 288, pp. 2023-31.96.Klovaite J, Benn M, Nordestgaard BG. Obesity as a causal risk factorfor deep venous thrombosis: a Mendelian randomization study // J Intern Med,2015, Vol. 277, No. 5, pp.
573-84.97.Kohler HP, Stickland MH, Ossei-Gerning N, Carter A, Mikkola H,Grant PJ. Association of a Common Polymorphism in the Factor XIII Gene withMyocardial Infarction // Thromb Haemost, 1998, Vol. 79, No. 1, pp. 8-13.98.Kucher N, Koo S, Quiroz R, et al. Electronic alerts to prevent venousthromboembolism among hospitalised patients // N Engl J Med, 2005, No. 352,pp.
969–977.99.Kurth T, Everett BM, Buring JE, et al. Lipid levels and the risk ofischemic stroke in women // Neurology, 2007, No. 68, pp. 556–562.116100. Lande G, Dantec V, Trossaert M, Godin JF, Le Marec H. Doinherited prothrombotic factors have a role in myocardial infarction with normalcoronary arteriogram // J Intern Med, 1998, No. 244, pp. 543-544.101. Leander K, Wiman B, Hallqvist J, Sten-Linder M, de Faire U;Stockholm Heart Epidemiology Program. PAI-1 level and the PAI-1 4G/5Gpolymorphism in relation to risk of non-fatal myocardial infarction Results fromthe Stockholm Heart Epidemiology Program (SHEEP) // Thromb Haemost, 2003,Vol.
89, No. 6, pp. 1064-71.102. Liao S, Woulfe T, Hyder S, Merriman E, Simpson D, Chunilal S.Incidence of venous thromboembolism in different ethnic groups: a regionaldirect comparison study // J Thromb Haemost, 2014, Vol. 12, No. 2, pp. 214-9.103. Liew SC, Gupta ED. Methylenetetrahydrofolate reductase (MTHFR)C677T polymorphism: epidemiology, metabolism and the associated diseases //Eur J Med Genet, 2015, Vol. 58, No. 1, pp. 1-10.104. Lijnen HR.
Role of fibrinolysis in obesity and thrombosis // ThrombRes, 2009, No. 123, Suppl 4, pp. S46-9.105. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment ofburden of disease and injury attributable to 67 risk factors and risk factor clustersin 21 regions, 1990-2010: a systematic analysis for the Global Burden of DiseaseStudy 2010 // Lancet, 2013, No. 381, P. 628.106. Lindhoff-Last E, Luxembourg B. Evidence-based indications forthrombophilia screening // Vasa, 2008, Vol.
37, No. 1, pp. 19-30.107. Lloyd-Jones DM, Nam BH, D’Agostino RB Sr, et al. Parentalcardiovascular disease as a risk factor for cardiovascular disease in middleagedadults: a prospective study // JAMA, 2004, No. 291, pp. 2204–2211.108. Louis-Jacques AF, Maggio L, Romero ST. Prenatal Screening forThrombophilias: Indications and Controversies, an Update // Clin Lab Med, 2016,Vol. 36, No. 2, pp. 421-34.109.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
